Effectiveness and safety of secukinumab in patients with moderate‐severe psoriasis: A multicenter real‐life study

Abstract

This study assessed the effectiveness and safety of secukinumab in patients with moderate-severe psoriasis vulgaris in a real-world setting. A total of 120 patients (35.8% women; mean age 49.8 years) were enrolled. Mean PASI significantly decreased from 12.0 ± 6.6 at baseline to 4.7 ± 3.2 and 2.3 ± 4.0 at 3 and 12 months, respectively (P < .001). Patients with two or more lines of prior biological therapies had poorer persistence to therapy at 12 months (71%) vs those who were bio-naïve (93%) or patients with only one prior failure with a biological agent (88%) (logrank = 9.33; P = .009). Multivariate regression analysis showed that patients beyond the second line of treatment had an increased risk of discontinuing secukinumab (HR: 3.6; 95% CI 1.3-10.2), while those without comorbidities had a lower risk (HR: 0.31; 95% CI 0.1-0.8). Our study confirms the effectiveness and safety of secukinumab in a real-life setting for psoriatic disease.

Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry

“…Our 12‐month drug‐survival rates among biologic‐experienced patients of 65% for ixekizumab vs 34% for TNFi, and 54% for non‐ixekizumab IL‐17i initiators, are comparable to those recently reported for adalimumab (12 months survival: 55% for ixekizumab vs 47% for adalimumab) 3 and secukinumab (12 months survival: 57% for ixekizumab vs 50% for secukinumab) 25 . The higher drug survival observed among ixekizumab users is consistent despite most users being biologic‐experienced, a subgroup of patients who have been shown to have lower drug survival than biologic‐naïve users 38, 39 . Notably, drug survival for all three groups was similar for approximately 6 months, at which point the survival curves separated and ixekizumab performed better out to 24 months of follow‐up.…”

“…25 The higher drug survival observed among ixekizumab users is consistent despite most users being biologic-experienced, a subgroup of patients who have been shown to have lower drug survival than biologic-naïve users. 38,39 Notably, drug survival for all three groups was similar for approximately 6 months, at which point the survival curves separated and ixekizumab performed better out to 24 months of follow-up.…”

Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study

“…In psoriasis, the efficacy of IL-17 inhibition has been gradually accumulating, and realworld evidence of secukinumab treatment has confirmed its high effectiveness [25][26][27][28][29][30][31]. In a meta-analysis including 43 real-world studies of psoriatic patients treated with secukinumab, PASI 90 were achieved in 50, 53, and 60% of cases at 3, 6, and 12 months, and PASI 100 in 36, 46, and 51% of cases at 3, 6, and 12 months, respectively [31].…”

Multicenter Retrospective Study of Secukinumab Drug Survival in Psoriasis Patients in a Daily Practice Setting: A Long-Term Experience in Spain

“…Although some real-world evidence (RWE) studies reporting the rates of S-SEC in psoriasis patients are available [2][3][4][5][6][7][8][9][10][11][12][13][14][15], scarce evidence about survival C 2 years has been collected [16][17][18][19][20]. In most of the RWE studies included in two meta-analyses [6,13], the patients were followed for a period shorter than 1 year.…”

“…Secukinumab (SEC) is a fully human monoclonal IgG1/j isotype antibody that selectively binds to and neutralizes interleukin 17A (IL-17A), a proinflammatory cytokine with key involvement in the clinical manifestation of psoriasis [1]. Despite its high effectiveness and safety profile demonstrated in the treatment of moderateto-severe plaque psoriasis, there is limited and conflicting evidence over the real-world drug survival of secukinumab in patients with psoriasis [2][3][4][5][6][7][8][9][10][11][12][13][14][15], especially in the long term [16][17][18]. Moreover, there is also a great variability in the results related to the predictors of a greater or lesser survival.…”